Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy

Dong Yun Kim, Junyong Park

Research output: Contribution to journalReview article

Abstract

In the treatment of chronic hepatitis B (CHB) patients with drug resistance, rescue combination therapy leads to viral suppression in almost all patients. However, once it is achieved, lifelong maintenance especially, by using combination therapy is not always possible in a significant proportion of patients. At present, there is no consensus on whether it is possible to switch to monotherapy from combination therapy. However, there is robust evidence to support step-down therapy, which involves switching from combination therapy to monotherapy in antiviral resistant CHB patients who achieve complete viral response from combination therapy. We review the evidence in favor of switching to monotherapy in antiviral resistant CHB patients who achieve complete viral response by combination therapy.

Original languageEnglish
Pages (from-to)711-717
Number of pages7
JournalFuture Virology
Volume13
Issue number10
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Chronic Hepatitis B
Antiviral Agents
Therapeutics
Drug Repositioning
Drug Resistance
Maintenance

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

@article{1c364069c5f04bddb66f76b308d9d781,
title = "Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy",
abstract = "In the treatment of chronic hepatitis B (CHB) patients with drug resistance, rescue combination therapy leads to viral suppression in almost all patients. However, once it is achieved, lifelong maintenance especially, by using combination therapy is not always possible in a significant proportion of patients. At present, there is no consensus on whether it is possible to switch to monotherapy from combination therapy. However, there is robust evidence to support step-down therapy, which involves switching from combination therapy to monotherapy in antiviral resistant CHB patients who achieve complete viral response from combination therapy. We review the evidence in favor of switching to monotherapy in antiviral resistant CHB patients who achieve complete viral response by combination therapy.",
author = "Kim, {Dong Yun} and Junyong Park",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/fvl-2018-0078",
language = "English",
volume = "13",
pages = "711--717",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "10",

}

Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy. / Kim, Dong Yun; Park, Junyong.

In: Future Virology, Vol. 13, No. 10, 01.01.2018, p. 711-717.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy

AU - Kim, Dong Yun

AU - Park, Junyong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the treatment of chronic hepatitis B (CHB) patients with drug resistance, rescue combination therapy leads to viral suppression in almost all patients. However, once it is achieved, lifelong maintenance especially, by using combination therapy is not always possible in a significant proportion of patients. At present, there is no consensus on whether it is possible to switch to monotherapy from combination therapy. However, there is robust evidence to support step-down therapy, which involves switching from combination therapy to monotherapy in antiviral resistant CHB patients who achieve complete viral response from combination therapy. We review the evidence in favor of switching to monotherapy in antiviral resistant CHB patients who achieve complete viral response by combination therapy.

AB - In the treatment of chronic hepatitis B (CHB) patients with drug resistance, rescue combination therapy leads to viral suppression in almost all patients. However, once it is achieved, lifelong maintenance especially, by using combination therapy is not always possible in a significant proportion of patients. At present, there is no consensus on whether it is possible to switch to monotherapy from combination therapy. However, there is robust evidence to support step-down therapy, which involves switching from combination therapy to monotherapy in antiviral resistant CHB patients who achieve complete viral response from combination therapy. We review the evidence in favor of switching to monotherapy in antiviral resistant CHB patients who achieve complete viral response by combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=85054703604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054703604&partnerID=8YFLogxK

U2 - 10.2217/fvl-2018-0078

DO - 10.2217/fvl-2018-0078

M3 - Review article

VL - 13

SP - 711

EP - 717

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 10

ER -